Featured Exhibitor

INVEGA HAFYERATM (paliperidone palmitate) is the only schizophrenia medication that can help continuously control your symptoms with just 2 doses a year after being adequately treated with INVEGA SUSTENNA® (paliperidone palmitate) for at least 4 months or INVEGA TRINZA® (paliperidone palmitate) for one 3-month cycle. INVEGA HAFYERATM has the same medication for schizophrenia as INVEGA SUSTENNA® (paliperidone palmitate) and INVEGA TRINZA® (paliperidone palmitate) but is given once every 6 months. 

In making the transition to INVEGA HAFYERATM, you can feel confident that the schizophrenia medication you need is being gradually released into your system every day for 6 months to help control symptoms. And long-acting injections (LAIs) like INVEGA HAFYERATM can help delay another episode so you can focus more on what’s important to you: your hobbies, your goals, and your future. 

 In a pivotal long-term study, 90% of adult patients taking INVEGA SUSTENNA® did not experience a significant return of schizophrenia symptoms vs 66% of those not treated.

In a separate pivotal long-term study, 93% of adult patients taking INVEGA TRINZA® did not experience a significant return of schizophrenia symptoms vs 77% of those not treated.

A long-term, global clinical study was conducted to show whether INVEGA HAFYERATM was as effective as INVEGA TRINZA® in symptom control with similar safety and side effects. In this study, 92.5% of patients treated with INVEGA HAFYERATM and 95% of patients treated with INVEGA TRINZA® did not experience an episode at 12 months.

The Janssen portfolio of LAIs has 3 treatment options with the same active ingredient, designed to be gradually released to help control schizophrenia symptoms and delay time to another relapse in adults.